Corona drug could become a blockbuster for Pfizer

Frankfurt High numbers of infections and fear of the spread of the omicron variant make the fight against the corona pandemic difficult. Hopes rest on further developed vaccines, but also increasingly on Covid drugs. These will play a much bigger role in the next year than before and will likely bring the pharmaceutical companies well into the double-digit billions.

Many experts also see the US industry giant Pfizer with Paxlovid in a leading role when it comes to drugs. Analyst Geoffrey Porges from SVB Leerink believes the product will generate sales of $ 24 billion in the coming year and $ 33 billion in 2023.

The second important new development, albeit with slightly worse prospects, is the drug Lagrevio, whose active ingredient molnupiravir was developed by the US group Merck & Co and Ridgeback Biotherapeutics.